Silverback Asset Management »

Halozyme Therapeutics shares owned by Silverback Asset Management

Quarter-by-quarter ownership of Halozyme Therapeutics shares owned by Silverback Asset Management from 13F filings

Historical chart of Silverback Asset Management investment in Halozyme Therapeutics

Tip: Access up to 7 years of quarterly data

All positions including Halozyme Therapeutics held by Silverback Asset Management consolidated in one spreadsheet with up to 7 years of data

Download as csvDownload consolidated filings csv Download as ExcelDownload consolidated filings xlsx

Quarterly reported holdings in Halozyme Therapeutics by Silverback Asset Management

Quarter filed Position value Share count Share price at filing
2025-12-31 $11M 9.8M 1.08

More positions owned by Silverback Asset Management

Seagate Hdd Cayman Note 3.500% 6/0 (Principal)
Coinbase Global Note 0.500% 6/0 (Principal)
Iac 0.875 06/15/26 Cvt Note 0.875% 06/15 (Principal)
Bridgebio Pharma Note 2.250% 2/0 (Principal)
Tyler Tex Indpt Sch Dist Note 0.250% 3/1 (Principal)
On Semiconductor Corp Note 5/0 (Principal)
Jbt Marel Corporation Note 0.250% 5/1 (Principal)
Vishay Intertechnology Note 2.250% 9/1 (Principal)
Collegium Pharmaceutical Note 2.875% 2/1 (Principal)
Uber Technologies Note 0.875%12/0 (Principal)
Evergy Note 4.500%12/1 (Principal)
Varonis Sys Note 1.000% 9/1 (Principal)
Porch Group Debt 9.000% 5/1 (Principal)
Ezpw 3.750 12/15/29 Cvt Note 3.750% 12/15 (Principal)
Semtech Corp Note 1.625%11/0 (Principal)

View all positions for Silverback Asset Management

Top funds holding Halozyme Therapeutics

Citadel Advisors
M&G
Nuveen
DZ BANK AG Deutsche Zentral Genossenschafts Bank, Frankfurt am Main
Angelo, Gordon & Co
Silverback Asset Management
Point72 Asset Management
Calamos Advisors
MacKay Shields
Advent Capital Management
Colony
Water Island Capital
Bnp Paribas Investment Partners
Pier 88 Investment Partners
Huntington Asset Advisors

View all funds holding Halozyme Therapeutics